Invention facilitates treatment of larger tumors and is a significant leap forward in the field of cryoablationCAESAREA, Israel, Nov. 25, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance from the Japan Patent Office for its invention titled 'Cryogenic System with Mul ...

CAESAREA, Israel, Nov. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the nine months ended September 30, 2024 before the Nasdaq Stock Market opens on Tuesday, November 26, 2024. The Company will also discuss such results and oth ...

PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including breast surgeons, interventional radiologists, and breast imaging and pathology specialistsPRECICE is exclusively using ProSense® to treat all 233 Luminal A and B patients >50 years of age with early-stage breast cancer, a wider population of patients than ICE3  Article published in European Journal of Cancer Prevention describes the PRECICE study and presents the ...

FDA decision on marketing authorization expected in the first quarter of 2025CAESAREA, Israel, Nov. 8, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced the U.S. Food and Drug Administration's ("FDA") Medical Device Advisory Committee Panel's (the "Advisory Panel") favorable recommendation with 9 panelists voti ...

Comments from key stakeholders, including doctors, nurses, researchers, and breast cancer patients, are available on FDA website FDA Advisory Panel providing recommendations and vote on information concerning the benefit-risk profile for a De Novo marketing submission of the IceCure ProSense® Cryoablation System in earlystage low risk breast cancer scheduled for November 7, 2024 CAESAREA, Israel, Oct. 29, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ('IceCure', 'IceCure Medical' or the 'Company' ...

Innovative cryogenic system connector technology designed to improve usability and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel, Oct. 21, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance for its invention titled "Cryogenic Sys ...

Liquid nitrogen- (LN2) based ProSense® found to have favorable safety compared to argon-based cryoablation systems, as well as being more cost effective and easier to manage Independent study conducted at the European Institute of Oncology (IEO) demonstrates interventional radiology use cases for ProSense® for indications that are approved in various markets across the world CAESAREA, Israel, Sept. 16, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), ...

Public forum to evaluate ProSense® cryoablation as a minimally invasive alternative to lumpectomy for an estimated 70,000 women diagnosed in U.S. annually with early-stage low risk breast cancer FDA decision regarding marketing authorization of ProSense® expected by early 2025 CAESAREA, Israel, Sept. 12, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alter ...

Company presentation to focus on how IceCure's industry-leading ProSense® enables non-surgical treatment of benign and cancerous tumors and upcoming near-term regulatory and operating catalysts CAESAREA, Israel, Sept. 4, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the Company's Chief Executive ...

财务数据和关键指标变化 - 前6个月ProSense系统和一次性探针销售同比增长20%,达到1.65百万美元 [14][15] - 总收入增长6.5%至1.75百万美元,主要受益于ProSense销售增长,但被日本业务收入下降部分抵消 [15] - 毛利增长至799,000美元,毛利率保持在46% [16] - 非GAAP毛利增长46%至699,000美元,非GAAP毛利率提升至42% [16] - 总运营费用下降至7.68百万美元,主要由于研发和管理费用的减少 [17] - 净亏损收窄至670万美元,每股亏损0.14美元 [17] - 截至2024年6月30日,公司现金及等价物约1050万美元,2024年7月31日约1030万美元 [18] - 2024年上半年通过ATM融资筹集5.035百万美元 [18] 各条业务线数据和关键指标变化 - 欧洲、美国、日本和其他亚洲地区ProSense销售增长,但中国销售下降 [15] 各个市场数据和关键指标变化 - 中国市场销售在2024年上半年为零,公司表示中国市场销售情况不稳定,但仍对未来保持乐观 [27][28] 公司战略和发展方向及行业竞争 - 公司正专注于在美国市场推广ProSense治疗早期乳腺癌,计划在FDA咨询委员会会议后进行商业化推广 [20][22][23] - 公司正与日本合作伙伴Terumo合作,计划于2025年第一季度在日本申请ProSense监管批准 [25] - 公司正利用全球独立研究数据支持ProSense在美国的监管申请,并计划在未来几个月内参加多个医学会议进行推广 [13] 管理层对经营环境和未来前景的评论 - 公司对ProSense在美国市场的快速普及持乐观态度,认为FDA咨询委员会会议将有助于提高公众对ProSense的认知 [11][12] - 公司认为ProSense与当前标准手术治疗相比具有明显优势,有望获得强劲需求 [12] - 公司表示有充足的现金资源执行未来的临床、监管和商业目标 [18] 其他重要信息 - 公司CEO Eyal Shamir由于通讯网络问题无法参加此次电话会议 [5] - 公司高管将参加9月份在纽约举行的两个投资者会议 [19] 问答环节重要的提问和回答 问题1 **Anthony Vendetti 提问** 询问公司在美国市场的商业化计划,包括针对意见领袖医生和普通医生的策略 [20][22][23] **Ronen Tsimerman 回答** 公司已制定详细的5年商业化计划,包括与学会合作、培养意见领袖医生,以及在美国市场建立必要的销售团队支持预期的快速增长 [22][23] 问题2 **Kemp Dolliver 提问** 询问中国市场销售下滑的原因 [27][28] **Ronen Tsimerman 回答** 中国市场销售情况不稳定,有时集中在某一个季度,公司无法对中国市场做出明确预测,但仍对未来保持乐观 [28] 问题3 **Ben Haynor 提问** 询问公司如何看待独立研究结果显示ProSense在一些患者群体上的应用 [33][34][35][36] **Ronen Tsimerman 回答** 公司认为独立研究结果显示了医生对ProSense技术的广泛认可和应用潜力,这些数据对公司未来发展很重要 [34][36]